Wharton Business Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Wharton Business Group’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$202K	Sell	2,547 -192	-7%	-$15.5K	0.01%	138
2025 Q4	$225K	Buy	+2,739	New	+$212K	0.01%	133
2024 Q4	–	Sell	-3,616	Closed	-$252K	–	143
2024 Q3	$252K	Hold	3,616	–	–	0.01%	128
2024 Q2	$234K	Sell	3,616 -130	-3%	-$8.23K	0.01%	127
2024 Q1	$242K	Hold	3,746	–	–	0.01%	124
2023 Q4	$247K	Sell	3,746 -598	-14%	-$34.8K	0.01%	121
2023 Q3	$248K	Hold	4,344	–	–	0.01%	126
2023 Q2	$266K	Hold	4,344	–	–	0.02%	117
2023 Q1	$272K	Hold	4,344	–	–	0.02%	122
2022 Q4	$276K	Sell	4,344 -98	-2%	-$6.22K	0.02%	123
2022 Q3	$261K	Hold	4,442	–	–	0.02%	116
2022 Q2	$256K	Hold	4,442	–	–	0.02%	119
2022 Q1	$276K	Hold	4,442	–	–	0.02%	119
2021 Q4	$316K	Hold	4,442	–	–	0.02%	107
2021 Q3	$332K	Sell	4,442 -96	-2%	-$7.32K	0.03%	55
2021 Q2	$351K	Hold	4,538	–	–	0.03%	97
2021 Q1	$335K	Hold	4,538	–	–	0.03%	97
2020 Q4	$318K	Sell	4,538 -178	-4%	-$11.3K	0.03%	98
2020 Q3	$267K	Hold	4,716	–	–	0.02%	100
2020 Q2	$275K	Sell	4,716 -36	-0.8%	-$1.96K	0.03%	95
2020 Q1	$221K	Sell	4,752 -5,026	-51%	-$262K	0.03%	93
2019 Q4	$546K	Sell	9,778 -628	-6%	-$32.7K	0.05%	66
2019 Q3	$493K	Hold	10,406	–	–	0.05%	67
2019 Q2	$557K	Hold	10,406	–	–	0.06%	62
2019 Q1	$574K	Hold	10,406	–	–	0.06%	61
2018 Q4	$490K	Hold	10,406	–	–	0.06%	65
2018 Q3	$619K	Hold	10,406	–	–	0.06%	64
2018 Q2	$569K	Hold	10,406	–	–	0.06%	66
2018 Q1	$512K	Sell	10,406 -820	-7%	-$41.8K	0.05%	68
2017 Q4	$529K	Sell	11,226 -220	-2%	-$10.3K	0.05%	73
2017 Q3	$572K	Sell	11,446 -1,020	-8%	-$48.4K	0.06%	69
2017 Q2	$569K	Sell	12,466 -1,500	-11%	-$64.8K	0.06%	75
2017 Q1	$591K	Hold	13,966	–	–	0.06%	78
2016 Q4	$542K	Sell	13,966 -755	-5%	-$30.5K	0.06%	80
2016 Q3	$618K	Hold	14,721	–	–	0.08%	86
2016 Q2	$545K	Sell	14,721 -3,985	-21%	-$156K	0.06%	93
2016 Q1	$716K	Hold	18,706	–	–	0.08%	87
2015 Q4	$945K	Sell	18,706 -105	-0.6%	-$5.19K	0.09%	86
2015 Q3	$860K	Hold	18,811	–	–	0.08%	88
2015 Q2	$1.1K	Sell	18,811 -3,720	-17%	-$213K	0.07%	88
2015 Q1	$1.24M	Sell	22,531 -580	-3%	-$31.4K	0.1%	92
2014 Q4	$1.16M	Sell	23,111 -527	-2%	-$25.8K	0.1%	92
2014 Q3	$1.09M	Sell	23,638 -215	-0.9%	-$9.69K	0.1%	99
2014 Q2	$1.04M	Buy	23,853 +2,380	+11%	+$96.4K	0.12%	95
2014 Q1	$894K	Sell	21,473 -4,132	-16%	-$177K	0.07%	113
2013 Q4	$949K	Sell	25,605 -8,180	-24%	-$293K	0.08%	112
2013 Q3	$1.19M	Sell	33,785 -765	-2%	-$25.3K	0.1%	100
2013 Q2	$998K	Buy	+34,550	New	+$982K	0.09%	106

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Wharton Business Group's PBE Position: Q1 2026 in Review

Wharton Business Group reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 7% in Q1 2026, selling an estimated $15.5K and leaving 2,547 shares worth $202K. The position accounts for 0.01% of the portfolio, ranked #138.

Wharton Business Group first reported a position in PBE in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.24M in Q1 2015. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Wharton Business Group held 2,547 shares of Invesco Biotechnology & Genome ETF worth $202K as of Q1 2026.
Wharton Business Group sold 192 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $15.5K.
Invesco Biotechnology & Genome ETF made up 0.01% of Wharton Business Group's portfolio in Q1 2026, its #138 holding.
Wharton Business Group first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 48 quarters since.
Wharton Business Group's Invesco Biotechnology & Genome ETF position peaked at $1.24M in Q1 2015.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Wharton Business Group's 13F filing for Q1 2026, filed 7 May 2026.